Zumutor Biologics, a biotechnology startup in the immuno-oncology space, has raised $6.2 million in fresh funding led by Siana Capital, as it looks to get to phase 1 clinical trials in the US for its lead antibody molecule for prostate cancer (ZM 008) by the middle of next year.